

PerCP/Cyanine5.5 anti-mouse CD45.2 Antibody

Catalog# / Size	109827 / 25 µg 109828 / 100 µg
Clone	104
Regulatory Status	RUO
Other Names	Ly-5.2, LCA
Isotype	Mouse (SJL) IgG2a, κ
Description	CD45.2 is an alloantigen of CD45, expressed by Ly5.2 bearing mouse strains (e.g., A, AKR, BALB/c, CBA/Ca, CBA/J, C3H/He, C57BL, C57BR, C57L, C58, DBA/1, DBA/2, NZB, SWR, 129). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in the mouse that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Mouse
Immunogen	B10.S mouse thymocytes and splenocytes
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. * PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.
Excitation Laser	Blue Laser (488 nm)
Application Notes	The 104 antibody does not react with mouse cells expressing the CD45.1 alloantigen. Additional reported applications (for the relevant formats) include: immunoprecipitation ⁴ , <i>in vivo</i> and <i>in vitro</i> blocking of B cell responses ^{1,2} , and immunohistochemical staining of acetone-fixed frozen sections ³ .
Additional Product Notes	BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References	<ol style="list-style-type: none"> 1. Yakura H, <i>et al.</i> 1983. <i>J. Exp. Med.</i> 157:1077. (Block) 2. Yakura H, <i>et al.</i> 1986. <i>J. Immunol.</i> 136:2729. (Block) 3. Suzuki K, <i>et al.</i> 2000. <i>Immunity</i> 13:691. (IHC) 4. Shen FW, <i>et al.</i> 1986. <i>Immunogenetics</i> 24:146. (IP) 5. Baldwin TA and Hogquist KA. 2007. <i>J. Immunol.</i> 179:837.

6. Pascal V, *et al.* 2007. *J. Immunol.* 179:1751.
7. Burman AC, *et al.* 2007. *Blood* 110:1064.
8. Kincaid EZ, *et al.* 2007. *J. Immunol.* 179:3187.
9. Phan TG, *et al.* 2007. *Nature Immunol.* 8:992.
10. Nakano-Yokomizo T, *et al.* 2011. *J. Exp Med.* 208:1661. [PubMed](#)
11. Wen T, *et al.* 2013. *PNAS.* 110:6067. [PubMed](#)
12. Kohlmeier JE, *et al.* 2008. *Immunity.* 29:101. (FC) [PubMed](#)

Product Citations

1. Turner JS *et al.* 2018. *Cell reports.* 25(6):1395-1403 . [PubMed](#)
2. Yuzhu Hou *et al.* 2018. *Immunity.* 49(3):490-503 . [PubMed](#)
3. Stewart I *et al.* 2018. *Immunity.* 49(3):477-489 . [PubMed](#)
4. Hayatsu N *et al.* 2017. *Immunity.* 47(2):268-283 . [PubMed](#)
5. Fu B *et al.* 2017. *Immunity.* 47(6):1100-1113 . [PubMed](#)
6. Yap JY, *et al.* 2018. *Immunology.* 154:522. [PubMed](#)
7. Sivala S, *et al.* 2019. *J Clin Invest.* 130:1596. [PubMed](#)
8. Chen Z *et al.* 2019. *Immunity.* 51(5):840-855 . [PubMed](#)
9. Liu C *et al.* 2019. *Immunity.* 51(2):381-397 . [PubMed](#)
10. Samarchith P Kurup *et al.* 2019. *Cell host & microbe.* 25(4):565-577 . [PubMed](#)
11. Zhang LJ, *et al.* 2019. *Immunity.* 50:121. [PubMed](#)
12. Hulsmans M *et al.* 2017. *Cell.* 169(3):510-522 . [PubMed](#)
13. Isoda T *et al.* 2017. *Cell.* 171(1):103-119 . [PubMed](#)
14. Gundra UM, *et al.* 2017. *Nat Immunol.* 1.195833333. [PubMed](#)
15. Hong Y, *et al.* 2019. *J Extracell Vesicles.* 8:1670893. [PubMed](#)
16. Schadt L, *et al.* 2020. *Cell Reports.* 29(5):1236-1248.e7.. [PubMed](#)
17. Cabal-Hierro L, *et al.* 2020. *Nat Commun.* 11:1406. [PubMed](#)
18. Charpentier JC, *et al.* 2020. *Nat Commun.* 11:180. [PubMed](#)
19. Ramos CV, *et al.* 2020. *Cell Reports.* 32(3):107910. [PubMed](#)
20. Viny AD, *et al.* 2019. *Cell Stem Cell.* 25:682. [PubMed](#)
21. Forero A, *et al.* 2020. *Immunity.* 51(3):451-464. [PubMed](#)
22. Dong MB, *et al.* 2020. *Cell.* 178(5):1189-1204.e23.. [PubMed](#)
23. Hoyer FF, *et al.* 2020. *Immunity.* 51(5):899-914.e7.. [PubMed](#)
24. MacKinnon A, *et al.* 2011. *Am J Respir Crit Care Med.* 185:537. [PubMed](#)
25. Xia S, *et al.* 2014. *J Leukoc Biol.* 95:733. [PubMed](#)
26. Zhang K, *et al.* 2014. *PLoS Pathog.* 10:1004385. [PubMed](#)
27. Ikeda T, *et al.* 2014. *PLoS One.* 9:115198. [PubMed](#)
28. Calderon B, *et al.* 2015. *J Exp Med.* 212: 1497-1512. [PubMed](#)
29. Kan X, *et al.* 2015. *Cardiovasc Res.* 10.1093/cvr/cvv255. [PubMed](#)
30. Tian Y, *et al.* 2016. *J Immunol.* 196: 2153 - 2166. [PubMed](#)
31. Tian Y, *et al.* 2016. *J Immunol.* 197: 1308 - 1321. [PubMed](#)
32. Rodriguez-Ruiz M, *et al.* 2016. *Cancer Res.* 76: 5994 - 6005. [PubMed](#)
33. Martins R, *et al.* 2016. *Nat Immunol.* 17:1361-1372. [PubMed](#)
34. Ulland T, *et al.* 2016. *Nat Commun.* 7:13180. [PubMed](#)
35. Emal D, *et al.* 2016. *J Am Soc Nephrol.* 10.1681/ASN.2016030255. [PubMed](#)
36. Wang X, *et al.* 2016. *J Immunol.* 197(12):4750-4761. [PubMed](#)
37. Harsha Krovi S, *et al.* 2020. *Nat Commun.* 4.790277778. [PubMed](#)
38. Cao H, *et al.* 2020. *Front Pharmacol.* 11:578943. [PubMed](#)
39. Rothchild AC, *et al.* 2020. *Bio Protoc.* 10:00. [PubMed](#)
40. Evgin L, *et al.* 2020. *Nat Commun.* 2.671527778. [PubMed](#)
41. Melo-Silva CR, *et al.* 2021. *PLOS Pathogens.* 17(5):e1009593. [PubMed](#)
42. Venturutti L, *et al.* 2020. *Cell.* 182(2):297-316.e27. [PubMed](#)
43. Hirai T, *et al.* 2020. *Immunity.* 54(1):84-98.e5. [PubMed](#)
44. Chen Z, *et al.* 2021. *Cell.* 184(5):1262-1280.e22. [PubMed](#)
45. Delacher M, *et al.* 2021. *Immunity.* 54(4):702-720.e17. [PubMed](#)
46. Mitchell JE, *et al.* 2021. *Cell Reports.* 35(2):108966. [PubMed](#)
47. Yu K, *et al.* 2021. *Cell Reports.* 35(12):109273. [PubMed](#)
48. Olson GS, *et al.* 2021. *Cell Reports.* 35(9):109195. [PubMed](#)
49. Xu S, *et al.* 2021. *Immunity.* . [PubMed](#)
50. Giampazolias E, *et al.* 2021. *Cell.* . [PubMed](#)

RRID

AB_893352 (BioLegend Cat. No. 109827)
 AB_893350 (BioLegend Cat. No. 109828)

Antigen Details

Structure	Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution	All hematopoietic cells except mature erythrocytes and platelets of the CD45.2 strain of mice
Function	Phosphatase, T and B cell activation
Ligand/Receptor	Galectin-1, CD2, CD3, CD4
Biology Area	Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers

Molecular Family	CD Molecules
Antigen References	1. Suzuki K, <i>et al.</i> 2000. <i>Immunity</i> 13:691.
Gene ID	19264


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Biotin anti-mouse CD45.2, FITC anti-mouse CD45.2, PE anti-mouse CD45.2, Purified anti-mouse CD45.2, APC anti-mouse CD45.2, Alexa Fluor® 488 anti-mouse CD45.2, Alexa Fluor® 647 anti-mouse CD45.2, Pacific Blue™ anti-mouse CD45.2, Alexa Fluor® 700 anti-mouse CD45.2, APC/Cyanine7 anti-mouse CD45.2, PerCP anti-mouse CD45.2, PerCP/Cyanine5.5 anti-mouse CD45.2, PE/Cyanine7 anti-mouse CD45.2, Brilliant Violet 421™ anti-mouse CD45.2, Brilliant Violet 570™ anti-mouse CD45.2, Brilliant Violet 650™ anti-mouse CD45.2, Brilliant Violet 510™ anti-mouse CD45.2, Brilliant Violet 785™ anti-mouse CD45.2, Brilliant Violet 605™ anti-mouse CD45.2, Purified anti-mouse CD45.2 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD45.2, Brilliant Violet 711™ anti-mouse CD45.2, Alexa Fluor® 594 anti-mouse CD45.2, APC/Fire™ 750 anti-mouse CD45.2, TotalSeq™-A0157 anti-mouse CD45.2, TotalSeq™-B0157 anti-mouse CD45.2, TotalSeq™-C0157 anti-mouse CD45.2, Brilliant Violet 750™ anti-mouse CD45.2, Spark Blue™ 550 anti-mouse CD45.2, Spark NIR™ 685 anti-mouse CD45.2

Product Data



C57BL/6 mouse splenocytes stained with 104 PerCP/Cyanine5.5

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587